Full Text View
Tabular View
No Study Results Posted
Related Studies
Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer
This study has been completed.
Study NCT00433095   Information provided by Ludwig-Maximilians - University of Munich

First Received on February 7, 2007.   Last Updated on March 11, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Carcinoma Breast Stage IV
Additional conditions recognized in this trial
Breast Neoplasms
Carcinoma
More general conditions related to this trial
Breast Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Skin Diseases
Interventions listed in this trial
Navelbine
Herceptin
Navelbine (oraly)
Additional drug interventions recognized in this trial
Trastuzumab
Vinorelbine
More general drug interventions related to this trial
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Ludwig-Maximilians - University of Munich
Pierre Fabre Laboratories


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services